COSTA MESA, Calif., March 5, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern California, announced today the successful completion of a multi-Site phase I clinical trial in healthy volunteers and patients with mild to moderate asthma. The study objectives were to evaluate the safety and tolerability of a drug containing charge-stabilized, oxygen-based, nanostructures for asthma. The impact of the drug on various asthma response indicators and quality of life indicators were also explored. Healthy volunteers and asthmatics not receiving steroids were assessed following a single dose of the test drug. Subsequently, the new drug was assessed in asthma patients requiring inhaled steroids for up to 8 weeks of treatment, relative to placebo. WCCT Global was identified as a strategic choice for the sponsor due to WCCT Global's extensive experience in early development trials in both healthy volunteers and patients suffering from asthma with capabilities of multi-site clinical management. In fact, one of WCCT Global's clinical research sites is fully dedicated to asthma and allergy clinical research and is armed with a robust database of asthma patients of every severity. In addition, WCCT Global also has a large clinical pharmacology unit dedicated to phase I research in healthy volunteers. The sponsor recognized this expertise and selected WCCT Global to manage the entire trial. WCCT Global's Chief Operating Officer Jon Rojas stated, "When our client approached us about managing every aspect of their clinical study, we were able to offer them an efficient solution that would maximize all the participating site's efforts to complete the study within the set timelines."
When it came about that a full service CRO was needed to manage this project, WCCT Global was an intricate choice which enabled the success of this study across all sites. The final conclusion of the drug was that it is safe in high dosages.
More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
To find out more about WCCT Global's capabilities, CLICK HERE
Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global